Huh, 44,046 patient metformin prophylaxis study: 1% higher progression [p=0.11] and 4% fewer cases [p=0.82] https://c19p.org/huh2mf
copied to clipboard
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041
Retrospective database analysis showing no significant differences with pre-existing metformin use.
|
risk of progression, 1.0% higher, RR 1.01, p = 0.11, treatment 104 of 272 (38.2%), control 774 of 2,533 (30.6%), adjusted per study, multivariable.
|
|
risk of case, 4.0% lower, RR 0.96, p = 0.82, treatment 329 of 1,874 (17.6%), control 7,012 of 42,172 (16.6%), adjusted per study, multivariable.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Huh et al., 12/19/2020, retrospective, database analysis, South Korea, Asia, peer-reviewed, 8 authors.
huh2
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.